Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
NIDA shifts focus of grants to translational, genetic medicine
The National Institute on Drug Abuse has restructured its small business technology transfer and small business innovation research grant programs, which make up for roughly 2.8% of its annual budget, to focus on projects that aim to discover substance abuse treatments using translational and genetic medicine. "We're interested in areas of genetics, in terms of smoking cessation, pharmacogenomics, treatment of substance abuse, and particularly right now, issues related to prescription substance abuse," said NIDA official Jonathan D. Pollock. The NIH unit is also interested in supporting development and commercialization of biomarkers, stem cell reagents, genomic and proteomic data and related technologies.
Or we can send an email on your behalf